NCT04049994View on ClinicalTrials.gov

Immunomodulation Therapy for Urinary Tract Infections

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

September 4, 2023

Study Completion Date

October 31, 2023

Conditions
Spinal Cord InjuriesUrinary Tract Infections
Interventions
DRUG

Uro-Vaxom

Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.

DRUG

Placebo oral tablet

Placebo oral tablet

Trial Locations (1)

6207

Swiss Paraplegic Centre, Nottwil

All Listed Sponsors
collaborator

Swiss Spinal Cord Injury Cohort Study (SwiSCI)

UNKNOWN

lead

Swiss Paraplegic Research, Nottwil

NETWORK

NCT04049994 - Immunomodulation Therapy for Urinary Tract Infections | Biotech Hunter | Biotech Hunter